Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2015

Stewart A, Thavasu P, de Bono J S, Banerji U

Abstract excerpt

BACKGROUND: We aimed to understand the relative contributions of inhibiting MEK and AKT on cell growth to guide combinations of these agents. MATERIALS AND METHODS: A panel of 20 cell lines was exposed to either the MEK inhibitor, PD0325901, or AKT inhibitor, AKT 1/2 inhibitor. p-ERK and p-S6 ELISAs were used to define degrees of MEK and AKT inhibition, respectively. Growth inhibition to different degrees of MEK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Enzyme-Linked Immunosorbent Assay

Share to MAP Kinase Kinase 1

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 25908604
DOI: 10.1093/annonc/mdv188
PMCID: PMC4478974

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.PMID 25908604Read ↗

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.Semantic proximity Read ↗

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEKSemantic proximity Read ↗

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Semantic proximity Read ↗

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.Semantic proximity Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.Semantic proximity Read ↗

Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells.Semantic proximity Read ↗

BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.Semantic proximity Read ↗

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsSemantic proximity Read ↗

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.Semantic proximity Read ↗

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.Semantic proximity Read ↗

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.